Morphosys Ag

The University of Melbourne

Bayer Intellectual Property Gmbh

Stefan Steidl

Elisabeth Thomassen-Wolf

John Allan Hamilton

Andrew David Cook

Mark Winderlich

Lisa Rojkjaer

Susanne Krohn

David Richard Light

Renate Parry

Antje Kahnert

Stefan Hartle

Ulrike Schubert

Noboru Satozawa

Tara Renee Heitner Hansen

Stefan Haertle

Bodo Brocks

Daniela Della Ducata

Kai Rosport

Stephane Leclair

Amgad Shebl

Doug Schneider

Jutta Amersdorffer

Jutta Amersdorfer

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Nucleic acid encoding anti-GM-CSF antibodies

The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Treatment for rheumatoid arthritis

Methods of treatment using anti-GM-CSF antibodies

The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.

Method for treatment of osteoarthritis with C-Fms antagonists

Anti-GM-CSF antibodies

Use of M-CSF antibodies in the treatment of osteoarthritis or pain

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-mesothelin antibodies and uses thereof

Anti-GM-CSF antibodies and uses therefor

Growing community of inventors

Munich, Germany

Stefan Steidl